Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

@inproceedings{Najm2015DrugbasedMO,
  title={Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo},
  author={Fadi J. Najm and Mayur Madhavan and Anita Zaremba and Elizabeth H. Shick and Robert T. Karl and Daniel C Factor and Tyler E Miller and Zachary S. Nevin and Christopher Kantor and Alex Sargent and Kevin L. Quick and Daniela Schlatzer and Hong Tang and Ruben Papoian and Kyle R. Brimacombe and Min Shen and Matthew B. Boxer and Ajit Jadhav and Andrew P. Robinson and Joseph R Podojil and Stephen D Miller and Robert H. Miller and Paul J Tesar},
  booktitle={Nature},
  year={2015}
}
Multiple sclerosis involves an aberrant autoimmune response and progressive failure of remyelination in the central nervous system. Prevention of neural degeneration and subsequent disability requires remyelination through the generation of new oligodendrocytes, but current treatments exclusively target the immune system. Oligodendrocyte progenitor cells are stem cells in the central nervous system and the principal source of myelinating oligodendrocytes. These cells are abundant in… CONTINUE READING